OBJECTIVES:  To assess the financial impact of the introduction of AAS 100 mg, simvastatin 40 mg and ramipril 5-10 mg (Sincronium®) in the secondary prevention of cardiovascular events in adult patients with a recent or not recent history of acute myocardial infarction (MI), from the perspective of the Mexican Healthcare System. METHODS: Two scenarios were used, the current one, a reference scenario with the single-components (AAS 100 mg, simvastatin 40 mg and ramipril 5-10 mg) was compared against future scenario, using polypill (Sincronium®), assuming an initial penetration rate of 5% and annual increases of 10%, considering a time horizon of 5 years (2016 to 2020). Direct medical costs, as they are drugs administration, acute event and chronic events were considered. The target population was calculated based on the incidence of acute myocardial infarction in persons 40 years old and over, as well as the mortality of this event. The costs and results are presented in United States Dollar (USD, 2016) the epidemiological data and unit costs were obtained from country´s institutional sources (Mexico) and the literature. RESULTS: The average annual cost per patient was $845.84 USD for treatment with the single-component and treatment with the polypill (Sincronium®) was $851.00 USD. Based on the penetration rate, the time horizon and the estimated population (101,347 in 2016, 180,220 in 2017, 242,212 in 2018, 291,509 in 2019 and 331,237 in 2020) there is an additional average consumption of $355,172.95 USD which represents 0.0107% of the total budget allocated to medicines. CONCLUSIONS:  The introduction of the polypill in the public health sector does not represent a significant financial impact on the Mexican healthcare system’s budget.